JANX logo

Janux Therapeutics Inc. (JANX)

$14.91

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on JANX

Market cap

$909276718

EPS

-1.84

P/E ratio

--

Price to sales

63.79

Dividend yield

--

Beta

2.519787

Price on JANX

Previous close

$14.34

Today's open

$14.30

Day's range

$14.30 - $15.01

52 week range

$12.12 - $35.34

Profile about JANX

CEO

David Campbell

Employees

109

Headquarters

San Diego, CA

Exchange

NASDAQ Global Market

Shares outstanding

60984354

Issue type

Common Stock

JANX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on JANX

Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know

The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

news source

Zacks Investment Research • May 28, 2026

news preview

Here's Why You Should Add JANX Stock to Your Portfolio Now

Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.

news source

Zacks Investment Research • May 26, 2026

news preview

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update. "Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic,” said David Campbell, Ph.D., Pr.

news source

Business Wire • May 7, 2026

news preview

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.38 per share a year ago.

news source

Zacks Investment Research • May 8, 2026

news preview

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

news source

Zacks Investment Research • May 7, 2026

news preview

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation.

news source

Seeking Alpha • May 4, 2026

news preview

Undercovered Dozen: Western Digital, SAP, Toast, And More

The Undercovered Dozen series spotlights 12 lesser-covered stocks from the past week on Seeking Alpha. This week's edition covers articles published between April 24 and April 30, offering fresh investment ideas. The focus is on stocks that may offer unique opportunities due to limited analyst coverage.

news source

Seeking Alpha • May 5, 2026

news preview

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal revie.

news source

Business Wire • Apr 27, 2026

news preview

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux's tumor-activated technology pl.

news source

Business Wire • Apr 16, 2026

news preview

Janux Therapeutics Secures $35M Milestone Payment From BMY Deal

JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.

news source

Zacks Investment Research • Apr 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Janux Therapeutics Inc.

Open an M1 investment account to buy and sell Janux Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in JANX on M1